triple negative breast cancer

[Susan G. Komen®] Susan G. Komen® announced the addition of six esteemed breast cancer researchers and three new patient advocates to important advisory roles. These women and men join a group of breast cancer researchers, clinicians and advocates who help guide the organization’s $1.1 billion research program.

[ImmunityBio, Inc.] ImmunityBio, Inc. announced it has received FDA authorization to conduct a Phase Ib/II open-label study to evaluate the safety and preliminary efficacy of its superagonist Anktiva and PD-L1 targeted high-affinity natural killer (t-haNK) cells in combination with standard chemo and Trodelvy, in subjects with advanced TNBC.

[Cancer Research] Using a combination of in vivo and in vitro analyses in a novel PyMT-E2A conditional knockout mouse model and derived primary tumor cell lines, researchers reported an essential role of E2A in stemness, metastasis, and therapeutic resistance in breast cancer.

[Oncogene] Investigators found that Doxorubicin enhanced the oncolytic effect of the M1 virus by up to 100-fold specifically in TNBC in vitro, and significantly stalled the tumor growth of TNBC in vivo, through promoting intratumoral virus replication and further triggering apoptosis in addition to necroptosis.

[Cell Death & Disease] Researchers used Cell Counting Kit-8, colony formation, wound healing migration, Transwell invasion, and nude mouse xenograft assays to confirm the role of the lncRNA actin filament-associated protein 1 antisense RNA1 (AFAP1-AS1) in the proliferation, migration of TNBC cells in vitro and in vivo.

[Cells] Persistent cells were enriched for vimentinhigh sub-population, vimentin knockdown using siRNA approach decreased the invasive and sphere forming capacities as well as Akt phosphorylation in persistent cells, indicating that vimentin was involved in chemotherapeutic treatment-induced enhancement of TNBC aggressiveness.